Eisai announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a ground-breaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).
Eisai has announced that it will increase the number of sales representatives for the anti-...
Eisai filed litigation against the US Drug Enforcement Agency (DEA) Monday in a US Court of...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions.
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones
Japanese drug maker Eisai Co. said Friday its subsidiary in Taiwan has agreed to divest its plant in southern Taiwan to Taiwanese pharmaceutical firm Bora Corp. The divestment by Eisai Taiwan Inc. of its plant in Tainan, which has served as a production base for emerging markets, particularly in Asia, is expected to be completed by September, the parent company said.
Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological DiseasesDecember 13, 2012 3:20 am | News | Comments
UCL and the Japanese pharmaceutical company Eisai, today announce the agreement to establish a major drug discovery and development collaboration.
Biogen Idec and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both companies’ Research Triangle Park (RTP)-based facilities.
TRENTON, N.J. (AP) — A consumer group pressing the Food and Drug Administration to remove the highest dose of an Alzheimer's disease drug from the market is suing the agency for what it calls "foot-dragging."
Eisai Inc. and Arena Pharmaceuticals, Inc. announced today that Arena has transferred the BELVIQ (lorcaserin hydrochloride) New Drug Application (NDA) to Eisai.
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku Co., Ltd., pertaining to exclusive overseas marketing rights for the Aricept patch (once weekly donepezil HCl transdermal system).
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday that the FDA will make a new ruling on its obesity drug lorcaserin by June 27.
SAN DIEGO (AP) — Arena Pharmaceuticals Inc. said yesterday it has sent regulators more information about its experimental drug lorcaserin to treat obesity.
GENEVA (AP) — Eight drug makers have agreed to create a U.N.-administered pool of patented information and other data to spur new research into 21 tropical diseases and ailments, industry and U.N. officials said Wednesday.
Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg.
The National Institute for Health and Clinical Excellence released draft guidance Wednesday, recommending against NHS reimbursement of Eisai's Halaven (eribulin) as a treatment for advanced breast cancer.
Eisai announced today that the FDA issued a Complete Response Letter to Teikoku Pharma USA, Inc., regarding the New Drug Application (NDA) of the Aricept(R) Patch (donepezil transdermal system).
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., has announced plans to realign its operations in the United States. As part of this restructuring, Eisai Inc. will reduce its workforce by approximately 20 percent across all U.S. functions, eliminating approximately 600 positions in total by April 1, 2011.
FDA Agrees to Special Protocol Assessment (SPA) toEvaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINVJanuary 12, 2011 3:51 am | News | Comments
Helsinn Group and Eisai Inc. announced today that the FDA has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Eisai to Provide Medicine to Help World Health Organization (WHO) Combat Lymphatic Filariasis EpidemicNovember 19, 2010 3:52 am | News | Comments
Eisai Co., Ltd. has signed a statement of intent with the World Health Organization (WHO) to supply free of charge of a primary medicine for the treatment of lymphatic filariasis.
Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight LossNovember 9, 2010 3:51 am | News | Comments
Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes.
GENEVA (AP) — The World Health Organization estimated Thursday that 1 billion of the world's poorest people suffer from neglected tropical diseases such as dengue, rabies and leprosy that remain concentrated in remote rural areas and urban slums despite being mostly eradicated from large areas of the world.
Eisai Inc. today announced that the FDA has accepted for review the New Drug Application (NDA) for the Aricept(R) Patch (donepezil transdermal system). Teikoku Pharma USA, Inc., a subsidiary of Teikoku Seiyaku Co., Ltd., and Eisai are seeking approval of the weekly Aricept Patch in the treatment of mild, moderate and severe stages of Alzheimer's disease.
Eisai today announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with epilepsy.
Helsinn Healthcare S.A. and Eisai Inc. have announced the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the United States.
Eisai Submits Simultaneous Regulatory Applications for Approval of Eribulin Mesylate in Japan, U.S. and EUMarch 31, 2010 4:42 am | News | Comments
Eisai Inc. has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer to agencies in Japan, the United States and the European Union (EU)
- Page 1